NTLA-2001
Intellia Therapeutics
['cardio', 'cardiomyopathy', 'crispr']
new late-breaking data from #aha22 show ntla-2001, a novel crispr/cas90-based gene editing therapy, significantly reduced abnormal transthyretin protein levels in patients with attr amyloid cardiomyopathy. 
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.